Data / Drug companies / Vesicular Monoamine Transporter 2 Inhibitor
Vesicular Monoamine Transporter 2 Inhibitor drugs: 2 drugs from 13 companies in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Vesicular Monoamine Transporter 2 Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 30 products in this class from 13 companies, covering 2 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on September 1, 2025.
The request: Get every company that lists a Vesicular Monoamine Transporter 2 Inhibitor drug in the FDA NDC directory, with headquarters, website and size. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 13Companies
- 30Products
- 2Drugs by generic name
Drugs in the Vesicular Monoamine Transporter 2 Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Tetrabenazine | 24 | 12 |
| Valbenazine | 6 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Neurocrine Biosciences, Inc. | 6 | capsule | New drug applications (NDA) | April 30, 2024 |
| Ajanta Pharma USA Inc. | 2 | tablet | Generic drugs (ANDA) | December 27, 2020 |
| Apotex Corp. | 2 | tablet | Generic drugs (ANDA) | June 18, 2020 |
| Bionpharma Inc. | 2 | tablet | Generic drugs (ANDA) | January 15, 2018 |
| Camber Pharmaceuticals, Inc. | 2 | tablet, coated | Generic drugs (ANDA) | August 17, 2015 |
| Dr. Reddy's Laboratories Inc. | 2 | tablet | Generic drugs (ANDA) | January 8, 2018 |
| Golden State Medical Supply, Inc. | 2 | tablet | Generic drugs (ANDA) | March 17, 2020 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 2 | tablet | Generic drugs (ANDA) | September 1, 2025 |
| Lundbeck Pharmaceuticals LLC | 2 | tablet | New drug applications (NDA) | November 24, 2008 |
| Oceanside Pharmaceuticals | 2 | tablet | Authorized generics (NDA) | July 20, 2015 |
| Precision Dose, Inc. | 2 | tablet | Generic drugs (ANDA) | December 1, 2023 |
| Slate Run Pharmaceuticals, LLC | 2 | tablet | Generic drugs (ANDA) | March 2, 2020 |
| Sun Pharmaceutical Industries, Inc. | 2 | tablet | Generic drugs (ANDA) | August 17, 2015 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 22 | 73.3% |
| Capsule | 6 | 20% |
| Tablet, coated | 2 | 6.7% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.